• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 Management

AstraZeneca First Dose and mRNA Second Dose: How Does the ‘Mix & Match’ Immune Response Stack Up?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • In March 2021, Germany temporarily suspended administration of the adenoviral vector-based AstraZeneca COVID-19 vaccine due to incidence of thromboses
    • In response, revised recommendations suggested that individuals <60 years old that received a first dose of AstraZeneca should receive a second dose of a Pfizer or Moderna mRNA vaccine
  • Schmidt et al. (Nature Medicine, 2021) assessed the immunogenicity and reactogenicity of a heterologous vector/mRNA prime–booster regimen in comparison to the standard homologous regimens

METHODS:

  • Observational study
  • Participants
    • Healthy adults enrolled before their second dose of vaccine
    • At enrollment no participants had a known history of SARS-CoV-2 infection
  • Exposures
    • Hom vector: homologous vector/vector vaccine regimen
    • Hom mRNA: homologous mRNA/mRNA vaccine regimen
    • Het: heterologous vector/mRNA vaccine regimen
  • Study design
    • Spike-specific CD4 and CD8 T cells were identified using flow cytometry by induction of CD69 and the cytokines interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-2
    • Adverse events were recorded by questionnaire

RESULTS:

  • Hom vector: 55 individuals | Hom mRNA: 62 individuals | Het: 96 individuals
    • The time between doses was greater for regimens with vector vaccines, as per guidelines
      • Hom vector: 10.8 ± 1.4 weeks
      • Hom mRNA: 4.3 ± 1.1 weeks
      • Het: 11.2 ± 1.3 weeks
    • Individuals in the homologous vector group were slightly older than the other two groups
    • Lymphocyte and leukocyte counts did not differ between the groups
  • IgG levels were slightly lower with homologous vector vaccination, compared to the other groups (P<0.0001)
    • Hom vector: 404 (IQR 510) BAU ml–1
    • Hom mRNA: 4,932 (IQR 4,239) BAU ml–1
    • Het: 3,630 (IQR 3721) BAU ml–1
  • Additionally, CD4 T cell levels following homologous vector vaccination were significantly lower than the other groups (each P=0.0001)
    • Hom vector: median 0.04% (IQR 0.04%)
    • Hom mRNA: median 0.16% (IQR 0.19%)
    • Het: 0.17% (IQR 0.13%)
  • The heterologous vaccine regimen induced the highest percentages of spike-specific IFN-γ-producing CD8 T cells (P<0.0001)
    • Hom vector: 0.04% (IQR 0.08%)
    • Hom mRNA: 0.06% (IQR 0.19%)
    • Het: 0.28% (IQR 0.54%)
  • Spike-specific T cells were predominantly polyfunctional with largely overlapping cytokine-producing phenotypes in all three regimens
  • Side effects
    • First dose
      • Greater number of systemic adverse events were reported for vector vaccine as first dose
    • Second dose
      • Homologous vector regimen was associated with fewer systemic side effects after the second dose vs other groups

CONCLUSION:

  • A heterologous vaccine regimen of AstraZeneca followed by an mRNA vaccine induced strong humoral and cellular immune responses
  • This heterologous regimen was well tolerated, with side effect profiles comparable to those individuals who received two mRNA doses
  • The authors conclude

Although vaccine development focuses on antibodies due to their ability to confer sterilizing immunity, T cells are important in mediating protection from severe disease and may be less affected by virus variants.

The T cell data from this and similar studies could influence the development of future vaccine strategies, including how to improve vaccine-induced T cell immunity and protection from severe disease among vulnerable groups of immunocompromised patients

Learn More – Primary Sources:

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

mRNA-Based COVID-19 Vaccines Induce Robust, Persistent Immune Responses in Humans
Safety and Efficacy of AstraZeneca Oxford’s COVID-19 Vaccine
AstraZeneca and Pfizer Side Effects and Efficacy: Real World Data from the UK
Potential Pathology Behind AstraZeneca COVID-19 Vaccination and Blood Clots

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site